Oneness Biotech Co Ltd 2024 AR2
The report outlines Oneness Biotech Co., Ltd.'s business operations, corporate governance, and sustainability performance for the fiscal year 2024. Key highlights include the global expansion of its diabetic foot ulcer drug, Fespixon®, and the medical device, Bonvadis®, which received marketing authorizations in several countries. The company achieved high rankings in the S&P Global Corporate Sustainability Assessment (CSA) and was included in the Sustainability Yearbook for the third consecutive year. Additionally, Oneness Biotech implemented carbon reduction initiatives, setting a target to reduce emissions by 20% by 2030, and expanded its renewable energy capacity with solar power installations.
Company: Oneness Biotech Co Ltd
Sector: Health Care
Country: Taiwan
Year: 2024
Type: AR2
Pages: 188
Oneness Biotech Co Ltd
Annual Report
The report outlines Oneness Biotech Co., Ltd.'s business operations, corporate governance, and sustainability performance for the fiscal year 2024. Key highlights include the global expansion of its diabetic foot ulcer drug, Fespixon®, and the medical device, Bonvadis®, which received marketing authorizations in several countries. The company achieved high rankings in the S&P Global Corporate Sustainability Assessment (CSA) and was included in the Sustainability Yearbook for the third consecutive year. Additionally, Oneness Biotech implemented carbon reduction initiatives, setting a target to reduce emissions by 20% by 2030, and expanded its renewable energy capacity with solar power installations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees